Rani Therapeutics Holdings ... a lack of independent advancements or breakthroughs in their own product pipeline. The inclusion of forward-looking statements highlights potential risks and ...

Rani Therapeutics Holdings , Inc. (NASDAQ:RANI), a pharmaceutical company trading at $1.09 per share, disclosed on Monday that it has received a notice from the Nasdaq Stock Exchange regarding non ...

Rani Therapeutics announced positive preclinical data for RT-114 and semaglutide, advancing toward Phase 1 obesity trials in mid-2025. Rani Therapeutics Holdings, Inc. has announced preclinical ...

SAN JOSE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage ...

SAN JOSE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics” or "Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral ...

SAN JOSE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs ...

May 19, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of ...

Rani Therapeutics Holdings , Inc. (NASDAQ:RANI), a pharmaceutical company trading at $1.09 per share, disclosed on Monday that it has received a notice from the Nasdaq Stock Exchange regarding ...